Edition:
United States

People: Endo International PLC (ENDP.O)

ENDP.O on Nasdaq

9.97USD
24 Mar 2017
Change (% chg)

$-0.02 (-0.20%)
Prev Close
$9.99
Open
$10.01
Day's High
$10.10
Day's Low
$9.85
Volume
5,900,506
Avg. Vol
7,515,712
52-wk High
$35.34
52-wk Low
$9.70

De Silva, Rajiv 

Mr. Rajiv De Silva is President, Chief Executive Officer, Director of Endo Health Solutions Inc., since March 18, 2013. Prior to joining Endo in March 2013, Mr. De Silva served as the President of Valeant Pharmaceuticals International, Inc. from October 2010 to January 2013 and served as its Chief Operating Officer, Specialty Pharmaceuticals from January 2009 until January 2013. He was responsible for all specialty pharmaceutical operations, including sales and marketing, research and development, manufacturing and business development. He has broad international experience, having managed businesses in the United States, Europe, Canada, Latin America, Asia, South Africa and Australia/New Zealand. Prior to joining Valeant, Mr. De Silva held various leadership positions with Novartis. He served as President of Novartis Vaccines USA and Head, Vaccines of the Americas at Novartis. During this time, he played a key role at Novartis’ Vaccines & Diagnostics Division. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel, Switzerland. Prior to his time at Novartis, Mr. De Silva was a Principal at McKinsey & Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. Mr. De Silva has been a Director of AMAG Pharmaceuticals, Inc. since February 2012. He holds a Bachelor of Science in Engineering, Honors from Princeton University, a Master of Science from Stanford University and a Master of Business Administration with Distinction from the Wharton School at the University of Pennsylvania.

Basic Compensation

Total Annual Compensation, USD 6,465,620
Restricted Stock Awards, USD 4,782,990
Long-Term Incentive Plans, USD --
All Other, USD 1,345,440
Fiscal Year Total, USD 12,594,100

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --